香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 國藥集團藥業股份有限公司 2025 年半年度報告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 茲載列國藥控股股份有限公司旗下一間 A 股於上海證券交易所上市的附屬公司，國藥集團藥業 股份有限公司，於 2025 年 8 月 20 日於上海證券交易所網站刊發的《國藥集團藥業股份有限公 司 2025 年半年度報告》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 20 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 国药 ...

Core Points - The National Medical Insurance Administration has officially launched the 11th batch of centralized procurement, including 55 drug varieties after a rigorous three-stage selection process [1][2] - This batch introduces a new sales threshold of 100 million yuan, excluding 24 varieties with sales below this threshold, reflecting a focus on drug quality and innovation [1][2] - The selection process emphasizes intellectual property protection, excluding drugs with unexpired patents and those with high clinical risks [2][3] Selection Criteria - A total of 122 candidate varieties were initially screened, with 55 ultimately selected based on criteria such as market scale, clinical expert opinions, and risk assessments [2][3] - Selected drugs cover various therapeutic areas, including anti-infectives, anti-tumor, diabetes, and cardiovascular medications [2] - Specific selection criteria include having at least seven companies for reference formulations and a procurement amount exceeding 100 million yuan in 2024 [2][3] Quality Control Measures - The new procurement rules raise the qualification requirements for bidders, mandating at least two years of production experience for the drug's manufacturing entity [3] - The National Medical Products Administration will implement comprehensive inspections and product sampling to ensure the quality of selected drugs [3][4] - In 2024, the administration aims for 100% coverage of selected varieties and enterprises through a combination of national and local sampling [3][4] Reporting and Quoting Adjustments - The new rules allow medical institutions to report quantities based on specific brands rather than generic names, aligning supply with clinical needs [4][5] - Institutions are required to report quantities that are at least 80% of actual usage, with flexibility for adjustments based on clinical demand [4][5] - The procurement process will also address irrational low-price competition and supply risks through updated bidding rules and penalties [5][6] Policy Evolution - The 11th batch of procurement marks a shift from a focus solely on low prices to a dual emphasis on quality and price [7] - The centralized procurement initiative has been ongoing for seven years, covering 435 drug varieties and significantly reducing drug prices for the public [7]

Group 1: Company Performance - In 2024, the company achieved a historical high in revenue of 1.081 billion CNY, representing a year-on-year growth of 14.09% [3] - The net profit attributable to shareholders remained stable at 66.07 million CNY, consistent with the previous year [3] - Total assets reached 2.356 billion CNY, reflecting a year-on-year increase of 9.54% [3] Group 2: Business Strategy and Outlook - The company focuses on the pharmaceutical packaging and heat-resistant glass sectors, aiming to strengthen its position as a market leader [2] - There is an ongoing expansion of production capacity for borosilicate products, with expectations for continued growth in the future [3] - The company plans to enhance its market share in the pharmaceutical packaging sector by leveraging its technical reserves and customer resources [3] Group 3: Share Buyback and Financial Management - As of May 13, the company has repurchased 2,325,800 shares, accounting for 1.00% of the total share capital [4] - The buyback plan will continue based on market conditions [4] Group 4: International Expansion - The company has prioritized global development, with significant progress in Latin America and the Middle East [5] - In January 2024, the company signed an investment framework agreement to acquire 51% of The European Ampoules Company in Egypt [5] - A cooperation investment agreement was signed with SANTISA ABORATORIO FARMACEUTICO S/A in March 2025 to further expand market reach [6]